| pubmed-article:6986180 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6986180 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:6986180 | lifeskim:mentions | umls-concept:C1883018 | lld:lifeskim |
| pubmed-article:6986180 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:6986180 | lifeskim:mentions | umls-concept:C0439810 | lld:lifeskim |
| pubmed-article:6986180 | lifeskim:mentions | umls-concept:C1521827 | lld:lifeskim |
| pubmed-article:6986180 | lifeskim:mentions | umls-concept:C0024230 | lld:lifeskim |
| pubmed-article:6986180 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:6986180 | pubmed:dateCreated | 1980-4-17 | lld:pubmed |
| pubmed-article:6986180 | pubmed:abstractText | A new combination of total lymphoid irradiation and cyclophosphamide was used prior to bone marrow transplantation in an attempt to achieve decreased rejection rates and graft-versus-host disease. Nine previously transfused patients with severe aplastic anemia received marrow from an HLA-identical, MLC-compatible sibling following this preparative regimen. There were no episodes of graft rejection, and only one patient developed graft-versus-host disease. Of the 9 patients, 7 (78%) are surviving with a median follow-up of 400 days. The excellent results of this pretransplant combination of total lymphoid irradiation and cyclophosphamide warrants application of this regimen to a larger series of patients. | lld:pubmed |
| pubmed-article:6986180 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6986180 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6986180 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:6986180 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6986180 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6986180 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:6986180 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:6986180 | pubmed:author | pubmed-author:KrivitWW | lld:pubmed |
| pubmed-article:6986180 | pubmed:author | pubmed-author:KerseyJ HJH | lld:pubmed |
| pubmed-article:6986180 | pubmed:author | pubmed-author:LevittS HSH | lld:pubmed |
| pubmed-article:6986180 | pubmed:author | pubmed-author:NesbitM EME | lld:pubmed |
| pubmed-article:6986180 | pubmed:author | pubmed-author:KimTT | lld:pubmed |
| pubmed-article:6986180 | pubmed:author | pubmed-author:CocciaP FPF | lld:pubmed |
| pubmed-article:6986180 | pubmed:author | pubmed-author:RamsayN KNK | lld:pubmed |
| pubmed-article:6986180 | pubmed:author | pubmed-author:WoodsW GWG | lld:pubmed |
| pubmed-article:6986180 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6986180 | pubmed:volume | 55 | lld:pubmed |
| pubmed-article:6986180 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6986180 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6986180 | pubmed:pagination | 344-6 | lld:pubmed |
| pubmed-article:6986180 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:meshHeading | pubmed-meshheading:6986180-... | lld:pubmed |
| pubmed-article:6986180 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:6986180 | pubmed:articleTitle | Total lymphoid irradiation and cyclophosphamide as preparation for bone marrow transplantation in severe aplastic anemia. | lld:pubmed |
| pubmed-article:6986180 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6986180 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6986180 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6986180 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6986180 | lld:pubmed |
